Moderna, bird flu

Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
CDC upgrades its advisory on bird flu. Will Moderna’s stock get a boost?
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or bird.
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu. This funding, announced Friday by Moderna,
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a $590 million award from the U.S. Health and Human Services Department to accelerate its bird flu vaccine development.
Moderna secures $590M in government funding to develop bird flu vaccine
The U.S. government has awarded Moderna $590 million to help speed up the development of a bird flu vaccine. President Trump ends marathon inauguration day at three inaugural balls José Andrés Says This Is the Best Substitute for Salt Macron announces plan for mobilization of volunteers Real-life “Yellowstone” cowboy went from sleeping in a tent to a building a TV empire New Bears coach Ben Johnson eyeing two former NFL head coaches for his staff in Chicago,
bovnews3h
MRNA Unveiled: The Shocking Truth Behind Moderna Inc’s Latest Stock Movements
Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...
Moderna: Is Stock a Buy? Breaking Down the Latest Guidance
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
3-Stock Lunch: 3M, Moderna, & T-Mobile
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
Why Is Moderna Stock Trading Higher On Tuesday?
Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...
Moderna stock jumps on AI healthcare prospects
Investing.com -- Moderna , Inc. (NASDAQ: MRNA) shares surged 14% following remarks by Oracle (NYSE: ORCL) Chairman Larry ...
Top Stock Movers Now: Moderna, 3M, Walgreens, and More
U.S. equities rose at midday on optimism the new tariffs threatened by President Trump won't be as severe as initially believed.
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...